Operational Costs Compared: SG&A Analysis of Amgen Inc. and Bausch Health Companies Inc.

SG&A Trends: Amgen vs. Bausch Health Over a Decade

__timestampAmgen Inc.Bausch Health Companies Inc.
Wednesday, January 1, 201446990000002026300000
Thursday, January 1, 201548460000002682700000
Friday, January 1, 201650620000002810000000
Sunday, January 1, 201748700000002582000000
Monday, January 1, 201853320000002473000000
Tuesday, January 1, 201951500000002554000000
Wednesday, January 1, 202057300000002367000000
Friday, January 1, 202153680000002624000000
Saturday, January 1, 202254140000002625000000
Sunday, January 1, 202361790000002917000000
Monday, January 1, 20247096000000
Loading chart...

Cracking the code

A Decade of SG&A Trends: Amgen Inc. vs. Bausch Health

In the ever-evolving pharmaceutical industry, operational efficiency is key. Over the past decade, Amgen Inc. and Bausch Health Companies Inc. have showcased distinct strategies in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Amgen's SG&A expenses have grown by approximately 31%, peaking in 2023. This reflects a strategic investment in operational capabilities, possibly to support its expanding product portfolio. In contrast, Bausch Health's SG&A expenses have seen a more modest increase of around 44% over the same period, indicating a more conservative approach. Notably, Amgen's expenses consistently outpaced Bausch Health's, highlighting its aggressive market positioning. As the pharmaceutical landscape continues to shift, these trends offer a glimpse into the strategic priorities of two industry giants.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025